SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Home Bancorp announced third quarter 2026 financial results on October 19, 2026, reporting net income of $10.1 million ($1.28 diluted EPS), net interest income of $35.9 million, loans of $2.8 billion, and deposits of $3.1 billion. The earnings release was furnished as Exhibit 99.1 with detailed financial performance metrics, credit quality analysis, and capital ratios.
View raw filing on EDGAR →Darren E. Guidry was appointed as Chief Executive Officer effective January 8, 2027, following the retirement of John W. Bordelon. Guidry will continue to serve on both the Company and Bank's Board of Directors in connection with his promotion to CEO.
View raw filing on EDGAR →The Board of Directors declared a quarterly cash dividend of $0.32 per share, payable November 13, 2026 to shareholders of record as of November 2, 2026.
View raw filing on EDGAR →RBB Bancorp issued a press release on October 19, 2026 disclosing third quarter 2026 financial results for the period ended September 30, 2026, including net income of $12.6 million ($0.74 diluted EPS) and net interest margin of 3.16%. The company also announced a quarterly cash dividend of $0.16 per share and hosted a conference call on October 20, 2026 to discuss the results.
View raw filing on EDGAR →RBB Bancorp's Board declared a quarterly cash dividend of $0.16 per common share, payable November 12, 2026, to shareholders of record as of October 30, 2026.
View raw filing on EDGAR →The filing discloses both the departure of Adam Ciongoli as Chief Legal and Policy Officer and the appointment of Nicholas Trutanich as General Counsel effective December 1, 2026. While both events occur, the appointment of Trutanich to a senior legal role with specified compensation ($1.4M base, $1.4M target bonus, $2.2M annual equity target) is the principal forward-looking action. The departure is concurrent but secondary to the succession announcement. This is material as it involves a key executive leadership transition at a major public company.
View raw filing on EDGAR →GSK announced positive phase Ib clinical trial data for risvutatug rezetecan (Ris-Rez), an investigational B7-H3-targeted antibody-drug conjugate in extensive-stage small cell lung cancer, showing a 61% overall response rate at the 8 mg/kg dose. This is a material clinical development milestone supporting accelerated development and dose selection for an ongoing global phase III trial, representing significant progress in a key oncology program with multiple regulatory designations (Breakthrough Therapy, orphan drug, PRIME designation).
View raw filing on EDGAR →The press release announces the closing of a private placement of 4,247,500 units for gross proceeds of $1.7 million. This is a dilutive equity issuance to raise capital, with significant insider participation (1,500,000 FT Units to Chairman Robert Dickinson and associates, and 1,500,000 Units to The Sutton Group Inc., an insider). The proceeds are earmarked for exploration and working capital, and the securities are subject to a statutory hold period, consistent with a private placement structure typical of dilutive issuances at small- and mid-cap mining companies.
View raw filing on EDGAR →Peoples Bancorp of North Carolina Inc. issued a press release on October 19, 2026 announcing third quarter 2026 earnings results, furnished as Exhibit 99(a).
View raw filing on EDGAR →This 6-K discloses FDA approval of Jemperli (dostarlimab) as the first and only immunotherapy for MSI-H/dMMR locally advanced rectal cancer, based on positive AZUR-1 trial data showing 68% of patients achieved sustained clinical complete responses at 12 months with no disease recurrences reported among responders after median follow-up exceeding two years. This is a material regulatory and commercial milestone for GSK's oncology portfolio that would affect a reasonable investor's assessment of the company's product pipeline and revenue prospects, but does not fit a discrete event category (not an earnings release, M&A activity, executive change, or other named type) and is therefore best classified as an operational milestone—specifically a material product approval and regulatory achievement.
View raw filing on EDGAR →Atkore Inc. completed a merger transaction in which shareholders received $95.00 per share in cash consideration, with aggregate merger consideration of approximately $3.3 billion. The company became a wholly owned subsidiary of the Buyer, resulting in a change of control, delisting from the NYSE, and complete replacement of the board and executive officers.
View raw filing on EDGAR →Samantha L. Stoddard, Executive Vice President and Chief Financial Officer, resigned effective November 13, 2026, to pursue a professional opportunity outside the building products industry. Jeffrey Embt was appointed as Interim CFO.
View raw filing on EDGAR →ProPetro appointed Kyle Crowley as an independent director of its Board effective October 16, 2026, in connection with an increase in Board size. Crowley, who brings 30+ years of power and energy experience including 21 years at Exelon in senior roles including M&A leadership, meets NYSE independence requirements and qualifies as an audit committee financial expert, supporting the company's PROPWR growth initiative.
View raw filing on EDGAR →This is a notification of a relevant change to a significant shareholder under AIM Rules. BlackRock, Inc. crossed a notification threshold on October 15, 2026, with a resulting position of 6.14% of voting rights (4.91% direct shares plus 1.23% through financial instruments). While not a traditional governance event like an executive appointment or board change, this disclosure of a major shareholder crossing a regulatory threshold is a governance matter affecting the company's shareholder structure and control dynamics, material to investors assessing ownership concentration and potential influence.
View raw filing on EDGAR →The Company entered into a Membership Interest Purchase Agreement on October 13, 2026, selling seven percent (7%) membership interest units in Adia Labs LLC to CEO Larry A. Powalisz for $350,000. This constitutes a material disposition of equity interests in a subsidiary entity, fitting the definition of M&A activity under Item 1.01. The transaction involves a related-party sale with governance safeguards (independent director approval of proceeds use), indicating materiality to investors assessing control and capital allocation.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of Empery Digital's October 14, 2026 annual meeting of stockholders, including voting outcomes on three proposals: election of nine directors, approval/rejection of the 2025 Equity Incentive Plan, and ratification of MaloneBailey, LLP as independent auditors. The detailed vote tallies (For/Against/Withhold/Abstain) for each proposal are the core disclosure, making this a textbook shareholder_vote_results event. The material governance contest noted at the end (ATG's Section 225 action to sterilize votes and replace Ian Read with Gabriel Gliksberg) underscores the materiality of these voting outcomes to investors.
View raw filing on EDGAR →This Item 3.02 disclosure describes an unregistered private placement of preferred stock to accredited investors under Regulation D Rule 506(b). The Company issued 210,135 shares of Series 2025 Preferred Stock during the reporting period, raising approximately $2.1 million in aggregate proceeds. As of the filing date, 12.9 million shares of this series were outstanding, indicating substantial ongoing dilution. This is a classic dilutive equity issuance material to investors assessing the registrant's capital structure and ownership.
View raw filing on EDGAR →This exhibit is a press release announcing drill results from Scorpio Gold's Phase Two diamond drilling program at the Manhattan District Project in Nevada. The disclosure reports assay results from eight drill holes (26MN-117, 26MN-119 through 26MN-125), with highlights including 2.94 g/t gold over 36.42 metres at the Goldwedge target and 24.85 g/t gold over 1.22 metres at West Pit. The company also discusses plans for an underground restart at Goldwedge and a sonic drill program for heap leach testing. This is a material operational/exploration milestone for a junior mining company that would affect investor assessment of the project's prospectivity and near-term production potential.
View raw filing on EDGAR →Curaleaf's October 19, 2026 press release responds to Aurora's rejection of Curaleaf's enhanced acquisition proposal, detailing the terms of the hostile bid (86% premium to Aurora's unaffected share price, 217% ex-cash premium) and challenging Aurora's Board's rationale for rejecting the offer. This disclosure directly concerns an ongoing material acquisition attempt—a change-of-control transaction—and is central to the 8-K filing under Item 8.01 (Other Events). The press release references Curaleaf's binding offer to purchase all outstanding common shares of Aurora and disputes Aurora's valuation arguments, making this a material M&A event requiring investor disclosure.
View raw filing on EDGAR →This exhibit is a press release announcing BioNTech's presentation of clinical trial data at the ESMO 2026 Congress, featuring 16 abstracts across multiple oncology programs. The disclosure highlights late-stage pipeline progress for key candidates (pumitamig, elfetabart drozuntecan, gotistobart, and others) with new Phase 2 data from global trials in lung cancer, breast cancer, neuroendocrine neoplasms, and other solid tumors. While not a discrete M&A, financing, or governance event, this represents material operational and strategic progress in the company's clinical development pipeline that would affect a reasonable investor's assessment of BioNTech's oncology prospects and competitive positioning.
View raw filing on EDGAR →SpyGlass Pharma disclosed positive interim 4-year data from its first-in-human trial of the Bimatoprost Drug Pad-IOL System, showing 37% IOP reduction, 86% of patients off topical drops, and no product-related adverse events. This is a material clinical milestone for a late-stage biopharmaceutical company's lead product candidate advancing toward Phase 3 trials and potential NDA submission, but it does not fit the earnings_release category (which typically covers financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant product development milestone that would affect investor assessment of the company's pipeline progress.
View raw filing on EDGAR →Will Langley was appointed as Interim Chief Financial Officer of Torrid Holdings Inc., effective October 28, 2026, with a base salary of $702,000 and a 65% target bonus, following the planned departure of Paula Dempsey effective November 12, 2026.
View raw filing on EDGAR →ZoomInfo disclosed execution of a memorandum of understanding on October 16, 2026, settling a putative securities class action lawsuit for $44 million. Although filed under Item 1.01 (Material Definitive Agreement), the substance is a material litigation settlement—the core event is resolution of a securities class action alleging false statements about the Company's business and COVID-19 pandemic effects. The $44 million settlement amount and the Company's acknowledgment that resolving the litigation is in the best interests of stockholders establish materiality to a reasonable investor.
View raw filing on EDGAR →The filing discloses two distinct operational/financial developments: (1) an increase in SOL treasury holdings by 3,983 SOL to approximately 2,590,266 SOL, which is material to DFDV's core treasury strategy and per-share SOL accumulation; and (2) an increase in the CHAD preferred stock annual dividend rate from 13% to 14% effective November 2, 2026. While the dividend increase could be classified as `dividend_distribution`, the primary focus of the Item 8.01 disclosure is the treasury accumulation strategy and the strategic positioning ahead of Solana's Alpenglow upgrade. The combination of treasury growth and dividend rate adjustment, neither fitting neatly into a single named category, warrants `operational_other` as the most appropriate classification for this strategic business update.
View raw filing on EDGAR →PLAYSTUDIOS received written notification from Nasdaq on October 15, 2026, confirming regained compliance with the $1.00 minimum bid price requirement after previously receiving a non-compliance notice on November 5, 2025. The company executed a 1-for-10 reverse stock split on September 30, 2026, to remedy the deficiency. This disclosure directly addresses delisting risk—the resolution of a material listing qualification failure that threatened continued trading on Nasdaq Capital Market.
View raw filing on EDGAR →Veradermics announced positive Phase 3 clinical trial results for VDPHL01 in male pattern hair loss, with the drug meeting all primary and secondary endpoints with high statistical significance. This represents a material operational and clinical milestone for the late-stage biopharmaceutical company, demonstrating efficacy and safety data that support potential FDA approval and commercialization of its lead product candidate.
View raw filing on EDGAR →Shareholders approved an Extraordinary General Meeting on October 13, 2026, voting to extend the business combination deadline to February 19, 2027, amend the trust agreement to permit monthly extensions, and adjourn the meeting. All three proposals passed with substantial majorities (6,745,828 for, 1,665,624 against).
View raw filing on EDGAR →The exhibit is primarily a press release announcing preliminary unaudited third-quarter 2026 financial results, including revenue of $56.8 million, record biomass production of 317,000 pounds, and gross profit of $14.9 million. While the release also discloses the resignation of director John Nichols Jr., the dominant substance is the earnings announcement. The financial results are material to investors assessing the company's operational performance and cash position.
View raw filing on EDGAR →Inter & Co announces the completion of the Selection Period and commencement of the Subsequent Period for discontinuation of its Level II Sponsored BDR Program (ticker INBR32). The disclosure details the transition steps: delivery of Unsponsored Level I BDRs (INBR34) to eligible holders on October 21, 2026, and implementation of a Sales Facility for unelected shares to be sold on Nasdaq by Banco Bradesco. This is a material operational restructuring of the company's depositary receipt program affecting shareholder liquidity and trading options, though it does not fit the specific categories of M&A, workforce reduction, or other named operational events.
View raw filing on EDGAR →Inter & Co's subsidiary Banco Inter has entered into a Share Purchase Agreement to acquire 39.75% of Inter Seguros from Wiz for R$409.5 million, with completion contingent on Central Bank of Brazil and CADE approval. Upon closing, Banco Inter will become the sole shareholder. This is a material acquisition activity that increases the Company's ownership stake in a strategic insurance business already serving 9 million active contracts and integrated into the Inter Super App.
View raw filing on EDGAR →The filing discloses the appointment of two new directors, Kristine Peterson and Lonnel Coats, to the Board effective October 19, 2026, increasing Board size from seven to nine members. While the disclosure also includes compensatory arrangements (equity grants and cash compensation), the principal disclosed action is the appointment of these individuals to director roles. This is material as board composition changes affect governance and investor assessment of the company.
View raw filing on EDGAR →The Fund is implementing material changes to its investment policies and portfolio strategy effective October 19, 2026, including the creation of Cayman Islands subsidiaries to access Regulation S securities and TEFRA bonds, expansion of currency exposure (up to 10% non-U.S. denominated securities), and new exposure to contingent capital securities (up to 20% of Managed Assets). These policy changes materially alter the Fund's investment scope and risk profile, warranting disclosure under Item 8.01 as a significant operational and strategic business event affecting the Fund's investment approach.
View raw filing on EDGAR →David Yablunosky ceased to serve as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer of Innventure, Inc. on October 19, 2026. The filing discloses a consulting agreement with severance-like terms including weekly payments, COBRA reimbursement, and continued equity vesting.
View raw filing on EDGAR →Chief Growth Officer Roland Austrup's service will end on October 31, 2026, as part of an executive transition that includes the appointment of Eric Stober as Chief Financial Officer.
View raw filing on EDGAR →Stonepeak-Plus Infrastructure Fund LP sold approximately $38.8 million in unregistered limited partnership units to third-party investors on October 1, 2026, pursuant to Section 4(a)(2) and Regulation D exemptions, representing a material private placement that affects the Fund's capital structure and dilution to existing unitholders.
View raw filing on EDGAR →The Fund declared distributions to unitholders across multiple fund classes with per-unit amounts ranging from $0.2401 to $0.2800, payable on or about October 27, 2026.
View raw filing on EDGAR →Teamshares entered into a new $130 million senior secured term loan facility arranged by Sound Point Capital affiliates, maturing in October 2030 at SOFR + 9.50%, to refinance and repay a $150 million legacy credit facility. The refinancing is expected to reduce annual interest expense by approximately $5 million and addresses near-term maturity concerns while enabling acquisition growth.
View raw filing on EDGAR →Fernando Martins Jose Maria was appointed to serve as a member of the Board of Directors of Elventix Technology Corporation effective immediately on October 19, 2026. The disclosure centers on the appointment action itself, with background on his professional experience and confirmation of no conflicts or family relationships. Board appointments are material governance events affecting the composition and oversight of the company.
View raw filing on EDGAR →The filing discloses a declaration by the Board of Directors of a regular quarterly cash dividend of $0.29 per share, payable November 6, 2026, to shareholders of record as of November 2, 2026. The press release explicitly notes this represents an increase of $0.04 per share over the previous quarterly dividend, signaling a material capital allocation decision that would affect investor assessment of the company's financial health and shareholder returns.
View raw filing on EDGAR →FirstEnergy Pennsylvania Electric Company announced an extension of its exchange offer to swap $300 million of 4.150% Senior Notes due 2028 and $550 million of 4.550% Senior Notes due 2031 (unregistered) for registered notes of the same principal amount and terms. While technically an exchange rather than a new issuance, this involves the creation of registered debt securities ($850 million aggregate) and represents a material capital structure event. The high tender rate (99.4%) and extension of the offer deadline indicate significant investor participation and materiality to the registrant's financial obligations.
View raw filing on EDGAR →GreenPower converted $1,999,750 in convertible debentures into 2,105 Series B Convertible Preferred Shares and issued 360,572 common shares for accrued interest and dividends. The press release explicitly states this was a strategic decision to improve shareholders' equity and align with Nasdaq's minimum equity requirements. The issuance is material because it involves significant dilution to existing shareholders (360,572 common shares issued plus convertible preferred shares), affects insider ownership materially (Atkinson's stake increased from 27.8% to 29.3% on a non-diluted basis), and directly addresses balance-sheet concerns tied to exchange listing compliance.
View raw filing on EDGAR →Two directors, Gary S. Maier and John M. Palumbo, resigned effective October 15, 2026. The disclosure explicitly states the resignations were not due to disagreement with the Company, board, attorneys, or auditors. This is a straightforward director departure event under Item 5.02, material because it affects board composition and governance structure.
View raw filing on EDGAR →This exhibit discloses Emera's entry into an arrangement agreement to acquire all issued and outstanding shares of ATCO and Canadian Utilities (not held by ATCO) in exchange for Emera common shares, effective October 6, 2026. The transaction includes a spin-out of ATCO's industrial services business to SpinCo. This is a material acquisition and change-of-control transaction requiring shareholder approval and regulatory clearance, with detailed terms, conditions, fairness opinions, and termination fees ($432M, $634M, and $720M) specified in the arrangement agreement.
View raw filing on EDGAR →On October 14, 2026, the Company's audit committee concluded that the unaudited condensed financial statements in the Q2 10-Q should be restated to correct identified errors in proceeds contributed to the trust account, private placement units, Class A ordinary shares subject to redemption, and warrants. Amendment No. 1 to the Q2 10-Q was filed to reflect these corrections.
View raw filing on EDGAR →Two executive departures were disclosed: Anna Brunelle resigned from the Board and its committees effective October 13, 2026, and Tom Watson resigned as Chief Operating Officer effective October 14, 2026. These departures occurred during a period when the Company was addressing material accounting restatements.
View raw filing on EDGAR →On October 16, 2026, Archimedes Tech SPAC Partners II Co. shareholders voted to approve a material business combination with Forge Nano, Inc., with the Business Combination Proposal receiving 15,416,866 votes in favor versus 1,113,414 against, along with approval of related proposals including director elections, stock issuance, and organizational documents.
View raw filing on EDGAR →The company reports the expiration of the redemption deadline for an Extraordinary General Meeting of shareholders scheduled for October 19, 2026, with 3,895,270 public shares tendered for redemption as of the deadline. This disclosure reflects material governance activity regarding shareholder redemption rights and capital structure ahead of a critical shareholder vote.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of AeroVironment's 2026 Annual Meeting of Stockholders held on September 24, 2026, including voting outcomes for three proposals: election of five directors, ratification of Deloitte & Touche LLP as independent auditors, and an advisory vote on named executive officer compensation. The filing presents vote tallies (For, Against, Abstain, Broker Non-Votes) for each matter, which is the core content of shareholder_vote_results disclosures.
View raw filing on EDGAR →The 6-K discloses POSCO HOLDINGS' response to media reports regarding a potential acquisition of HMM (a major shipping company valued at ~10 trillion won). The company confirms it has signed an MOU with Cleveland Cliffs as part of an overseas expansion strategy and states that discussions are underway regarding business structure and investment size, though no decisions have been finalized. This constitutes disclosure of M&A activity in progress, material to investors assessing the registrant's strategic direction and capital deployment.
View raw filing on EDGAR →Sagimet announced positive 52-week Phase 3 open-label extension trial results for denifanstat in acne, demonstrating proof-of-concept for its lead program, and terminated its at-the-market offering prospectus supplement.
View raw filing on EDGAR →